SCHEMBL19079791

SCHEMBL19079791

C=CCn1c(SCC(=O)c2ccc(F)cc2)nc2sc(C)c(C)c2c1=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.70
▸ SMN1; SMN2 Q16637 3/20 0.70
▸ POLB P06746 3/20 0.70
▸ KDM4E B2RXH2 4/20 0.67
▸ GFER P55789 1/20 0.67
▸ ALDH1A1 P00352 6/20 0.63
▸ MAPT P10636 5/20 0.61
▸ HPGD P15428 1/20 0.61
▸ ATM Q13315 1/20 0.61
▸ NPSR1 Q6W5P4 3/20 0.59
▸ HSD17B10 Q99714 2/20 0.59
▸ USP2 O75604 1/20 0.59
▸ MAPK10 P53779 1/20 0.59
▸ CREBBP Q92793 1/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ MEN1 O00255 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ RXFP1 Q9HBX9 1/20 0.58
▸ HTT P42858 2/20 0.58
▸ TSHR P16473 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19090711 0.83 LMNA (0.75) LMNASMN1; SMN2POLBKDM4EGFER
SCHEMBL19079790 0.82 LMNA (0.74) LMNASMN1; SMN2POLBKDM4EGFER
SCHEMBL19079778 0.82 RXFP1 (0.64) LMNASMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL19079789 0.78 KDM4E (0.64) LMNASMN1; SMN2POLBKDM4EGFER
SCHEMBL19079780 0.76 RXFP1 (0.67) LMNASMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL1101900 0.76 LMNA (0.77) LMNASMN1; SMN2POLBKDM4EGFER
SCHEMBL5805451 0.75 ALDH1A1 (0.77) LMNASMN1; SMN2POLBKDM4EGFER
SCHEMBL19090776 0.73 RXFP1 (0.65) LMNASMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL19079792 0.73 ALDH1A1 (0.75) LMNASMN1; SMN2POLBKDM4EALDH1A1
SCHEMBL19079781 0.73 MAPT (0.79) LMNASMN1; SMN2POLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10329304-B2 Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase VANDERBILT UNIVERSITY (US) 2019-06-25 — — US disclosed
US-20170190717-A1 Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase VANDERBILT UNIVERSITY 2017-07-06 — — US disclosed
US-20170190717-A1 Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase VANDERBILT UNIVERSITY 2017-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329304-B2 Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase PDE4A, PDE4B, PDE7A LMNA 3846/4885SMN1; SMN2 4025/4885POLB 2192/4885
US-20170190717-A1 Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase PDE4A, PDE4B, PDE7A LMNA 3846/4885SMN1; SMN2 4025/4885POLB 2192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback